Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 9 Depression 9 Anxiety Disorders 7 Neoplasm Metastasis 3 Melanoma 2 Depressive Disorder, Major 2 Wounds and Injuries 1 Trauma, Nervous System 1 Stress Disorders, Post-Traumatic 1 Pancreatic Neoplasms 1 Pain 1 Ovarian Neoplasms 1 Osteosarcoma 1 Opioid-Related Disorders 1 Lymphoma 1 Hospice 1 Hematopoietic and Lymphatic System Neoplasm 1 Hematologic Neoplasms 1 Gastrointestinal Neoplasms 1 Endocrine Gland Neoplasms 1 Depressive Disorder 1 Caregiver Distress 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Agnosia 1

Interventions

Bupivacaine 11 Ketamine 9 Ropivacaine 8 Morphine 8 Analgesics, Opioid 8 Acetaminophen 8 Fentanyl 7 Dexmedetomidine 7 Lidocaine 6 Anesthesia, General 6 Saline Solution 5 Anesthesia, Local 5 Acupuncture Therapy 5 parecoxib 4 Tramadol 4 Surveys and Questionnaires 4 Sodium Chloride 4 Pregabalin 4 Ethanol 4 Analgesia, Epidural 4 Transcutaneous Electric Nerve Stimulation 3 Radiofrequency Ablation 3 Propofol 3 Oxycodone 3 Ketorolac 3 Control Groups 3 Anesthetics, Local 3 trimebutine 3-thiocarbamoylbenzenesulfonate 2 Therapeutics 2 Tea 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Agnosia × Psilocybin × Clear all

NCT06001749 2025-12-16

Psilocybin in Cancer Pain Study

Dana-Farber Cancer Institute

Phase 2 Recruiting

Agnosia, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡